Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to evaluate the change in disease
activity following 12 weekly s.c. (under the skin) doses of NNC109-0012 compared to placebo
in subjects with active Rheumatoid Arthritis (RA).